Overview of ED Cream
Dosage StrengthL-Arginine HCl / L-Lysine HCl 7/7% 90 mL Pump
L-arginine, an important amino acid, has a synthetic derivative called arginine hydrochloride. In situations including panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, and issues with growth and stature, arginine hydrochloride may be used as a tool to help discover growth hormone deficit. The medication has also been employed in the evaluation of gigantism and acromegaly-related pituitary function. Additionally, patients with urea cycle abnormalities who have high ammonia concentrations can be treated with arginine injection. Patients with stable angina pectoris have been given arginine tablets, which are nutritional supplements, to increase their ability for exercise. 1 The FDA initially authorized arginine infusion in February 1973.
L-lysine must be consumed daily through diet or supplements since it is an essential amino acid that the body cannot produce on its own. The average American consumes more than 5 g of this amino acid every day. L-lysine is frequently used topically and orally to treat and prevent the clinical signs and symptoms of herpes simplex labialis. The FDA concluded in 1992 that there was no orally administered active ingredient recognized as safe and effective for over-the-counter usage to cure or relieve cold sore symptoms. In contrast to licensed OTC medications, L-lysine products are therefore sold as dietary supplements under the DSHEA. L-lysine is also used orally by athletes as a protein supplement to help them perform better; it is believed to speed up anabolic processes that encourage the growth of muscular tissue. Some writers have proposed using L-lysine as an osteoporosis treatment since it may be crucial for calcium absorption and balance.
1.Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Card 1997;80:331-333.
2.Arginine hydrochloride injection (R-GENE) package insert. Lake Forest, IL: Hospira Inc.; 2010 Jan.
3.Ammonul (sodium phenylacetate and sodium benzoate) injection package insert. Scottsdale, AZ: Ucyclyd Pharma Inc.; 2011 Jul
4.Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr 2001; 138: S30-S39.
5.Batshaw, ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138:S46-S55
6.Adrogue HJ, Madias NE: Management of life-threatening acid-base disorders. Second of two parts. N Eng J Med 1998;338:107-11.
7.Bode-Boger SM, Boger RH, Galland A. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol 1998; 46: 489-497.
8.Tangphao O, Grossmann M, Chalon S, et al. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol 1999; 47: 261-266.
9.Bushinsky DA, Gennari J. Life-threatening hyperkalemia induced by arginine. Annals of Internal Medicine 1978; 89: 632-634.
10.FDA: Arginine hydrochloride injection (marketed as R-Gene 10). FDA Drug Safety Newsletter 2009;2(2):16-18.
11.Mudge GH, Weiner IM. Agents affecting volume and composition of body fluids. Gilman AG, Rall TW, Nies AS, Taylor P, (eds.) In: Goodman and Gilman’s Pharmacological Basis of Therapeutics. 8th ed., New York, Pergamon Press. 1990:620, 696—97.
12.Hamilton C. Acid-base disorders Gilman AG, Wells BG, Dipiro JT, Schwinghammer TL, et al. (eds.) In: Pharmacotherapy Handbook. 5th ed., New York, Pergamon Press. 1993:753—61.
13.Mudge GH, Weiner IM. Agents affecting volume and composition of body fluids. Gilman AG, Rall TW, Nies AS, Taylor P, (eds.) In: Goodman and Gilman’s Pharmacological Basis of Therapeutics. 8th ed., New York, Pergamon Press. 1990:620, 696-97.
14.Hamilton C. Acid-base disorders Gilman AG, Wells BG, Dipiro JT, Schwinghammer TL, et al. (eds.) In: Pharmacotherapy Handbook. 5th ed., New York, Pergamon Press. 1993:753-61.
15.Colchicine Tablets, USP package insert. Corona, CA: Watson Laboratories, Inc.; 2001 Jun.
16.Bellward GD, Warren PM, Howald W, et al. Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses. Clin Pharmacol Ther 1977;22:92—9.
17.Nilsson M-I, Widerlov E, Meresaar U, et al. Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 1982;22:337—42.
18.Wolff K, Rostami-Hodjegan A, Hay AW, et al. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000;95:1771—83.
19.Dolophine® (methadone) package insert. Columbus, OH: Roxane Laboratories, Inc; 2006 Oct.
20.Batshaw, ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138:S46 S55
Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.